Collplant Biotechnologies Ltd current report, Q1 FY2018

Business Context and Reporting Period

This Form 6-K filing by CollPlant Holdings Ltd. covers the period of February 2018. The report discloses changes in the company's outstanding securities following an immediate report filed with the Israel Securities Authority and the Tel Aviv Stock Exchange on February 1, 2018.

Key Financial Metrics and Capital Structure

The filing focuses on capital structure adjustments rather than operational financial performance. As of February 1, 2018, the following securities were outstanding:

  • Ordinary Shares: 172,081,129 issued and outstanding (includes 920,461 treasury shares).
  • Employee Options (2010): 47,544,792 outstanding.
  • Warrants:
    • Series G: 9,296,284
    • Series H: 4,152,764
    • Series I: 13,745,025
    • Series K: 36,531,500
  • Convertible Debentures: Nos. 1 and 2 were reduced to 0 outstanding.
  • Pre-Funded Warrants: 39,322,742 (representing the conversion value of the debentures).

The filing text does not provide clear values for revenue, profit, cash flow, margins, or liquidity.

Material Changes Versus Prior Period

Two primary capital events occurred during this period:

  1. Employee Option Grant: The number of outstanding employee options increased by 300,000 due to new issuances.
  2. Debt Conversion: Convertible Debenture No. 1 (previously 16,021,371) and Convertible Debenture No. 2 (previously 23,301,371) were automatically converted into Pre-Funded Warrants. Consequently, the outstanding balance for these debentures dropped to zero.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document is strictly a notification of changes in the company's capital structure.

Investor Verification Checklist

  • Verify the terms and exercise price of the newly issued 300,000 employee options.
  • Confirm the conversion terms and expiration dates of the 39,322,742 Pre-Funded Warrants resulting from the debenture conversion.
  • Review the impact of the debt-to-equity conversion on the company's weighted average shares outstanding and potential dilution.
  • Check subsequent filings for any operational financial results, as this 6-K contains no revenue or earnings data.